Tickers

AMCX — Ticker Eval done nvidia/nemotron-3-ultra-550b-a55b:free

Requested 2026-09-25 08:47:10.836374 UTC · finished 2026-09-25 08:50:29.011378 UTC

1. Composite Trajectory Verdict

All three statements carry roughly equal weight because AMCX's business model relies on declining linear revenue, high content investment, and significant debt maturities requiring both earnings and cash flow to service and refinance obligations.

Composite Trajectory: Mixed

The income statement shows GAAP operating income improved annually due to lower impairments but adjusted operating income fell 26.8% YoY; the most recent six-month period shows a 63.4% drop in operating income and a swing to net loss. Cash flow from operations declined 18.6% annually and 41.1% in the first half of 2026. The balance sheet improved annually with debt principal reduced 24.9% and equity up 14.8%, but in the first half of 2026 equity fell 7.2% and cash declined 7.6% while debt was only modestly reduced. Thus, earnings and cash generation are deteriorating while the balance sheet shows mixed signals (annual improvement vs. recent erosion).

2. Red Flags

  • Revenue declining across all periods: FY2025 -4.5% YoY (10-K FY2025, Consolidated Statements of Operations); six months ended June 2026 -5.7% YoY (10-Q Q2 2026, Consolidated Statements of Operations).
  • GAAP operating income fell 63.4% in six months ended June 2026 vs 2025 (10-Q Q2 2026, Consolidated Statements of Operations).
  • Net income attributable to stockholders swung to -$40.8M in six months 2026 from +$68.3M in 2025 (10-Q Q2 2026, Consolidated Statements of Operations).
  • Cash from operations dropped 41.1% in six months 2026 vs 2025 (10-Q Q2 2026, Consolidated Statements of Cash Flows).
  • Free Cash Flow (non-GAAP) fell 43.1% in six months 2026 (10-Q Q2 2026, Non-GAAP Financial Measures).
  • Goodwill impairment of $93.4M in FY2025 for AMCNI reporting unit (10-K FY2025, Impairment and other charges).
  • Domestic Operations goodwill fair value exceeds carrying value by only 6%, sensitive to growth and WACC assumptions (10-K FY2025, Goodwill).
  • Net leverage ratio 4.41x as of Dec 2025; interest coverage 2.01x, with covenant minimum reduced to 1.50x via Amendment No. 5 (10-K FY2025, Debt Financing Agreements).
  • Revolving Credit Facility terminated in May 2026 (10-Q Q2 2026, Debt Transactions).
  • Exchange Offer increased principal of 2032 Secured Notes to ~$1.315B from $400M, with higher coupon (10.5% vs 10.25%) (10-Q Q2 2026, Supplemental Guarantor Financial Information).
  • Recurring restructuring charges: $26.5M in FY2025, $49.5M in FY2024, $5.7M in six months 2026 (10-K FY2025, Restructuring; 10-Q Q2 2026, Restructuring).
  • Customer Chapter 11 bankruptcy filing June 30, 2026 (10-Q Q2 2026, Customer Chapter 11 Bankruptcy).

3. Earnings Assessment (Income Statement)

Earnings Trajectory: Mixed

Overall Assessment: Annual GAAP operating income improved to $133.3M in FY2025 from -$39.6M in FY2024, driven by a $301.7M reduction in impairment and restructuring charges (10-K FY2025, Consolidated Results of Operations). However, adjusted operating income (non-GAAP) declined 26.8% to $411.9M (10-K FY2025, Non-GAAP Financial Measures). Revenue fell 4.5% YoY to $2.31B (10-K FY2025, Consolidated Statements of Operations). In the six months ended June 2026, revenue declined 5.7% to $1.09B, operating income fell 63.4% to $47.1M, and net income attributable to stockholders swung to a -$40.8M loss from +$68.3M (10-Q Q2 2026, Consolidated Statements of Operations). Domestic segment adjusted operating income dropped 38.8% and International segment adjusted operating income dropped 19.5% in the same period (10-Q Q2 2026, Segment Results of Operations). The annual improvement in GAAP operating income is primarily due to non-recurring impairment reductions, while the underlying adjusted operating income and recent quarterly GAAP results show clear deterioration.

4. Cash Generation Assessment (Statement of Cash Flows)

Cash Trajectory: Deteriorating

Overall Assessment: Net cash provided by operating activities declined 18.6% annually to $305.7M in FY2025 from $375.6M in FY2024 (10-K FY2025, Consolidated Statements of Cash Flows). In the six months ended June 2026, operating cash flow fell 41.1% to $124.7M from $211.6M in the prior year period (10-Q Q2 2026, Consolidated Statements of Cash Flows). Free cash flow (non-GAAP) decreased 17.7% annually to $272.4M and 43.1% in the first half of 2026 to $108.1M (10-K FY2025, Non-GAAP Financial Measures; 10-Q Q2 2026, Non-GAAP Financial Measures). Capital expenditures declined modestly in both periods. The sharp decline in operating cash flow in the most recent period, driven by lower net income before non-cash items and higher program rights payments relative to income, indicates a deteriorating cash generation trend.

5. Balance Sheet Assessment

Balance Sheet Trajectory: Mixed

Overall Assessment: As of December 31, 2025, total debt principal decreased 24.9% to $1.78B from $2.37B a year earlier (10-K FY2025, Debt Financing Agreements), total liabilities fell 14.6% to $2.92B (10-K FY2025, Consolidated Balance Sheets), and stockholders' equity rose 14.8% to $981.9M (10-K FY2025, Consolidated Balance Sheets). However, cash and cash equivalents fell 36.0% to $502.4M (10-K FY2025, Consolidated Balance Sheets). By June 30, 2026, cash further declined 7.6% to $464.0M, total liabilities decreased 4.9% to $2.78B, but stockholders' equity fell 7.2% to $911.2M due to the six-month net loss (10-Q Q2 2026, Consolidated Balance Sheets). Long-term debt (net) decreased 4.6% to $1.66B (10-Q Q2 2026, Consolidated Balance Sheets). The annual period shows deleveraging and equity growth, but the first half of 2026 shows equity erosion and cash burn, resulting in a mixed trajectory.

6. Data Gaps

  • Quarterly revenue, operating income, and cash flow for Q1 2026, Q3 2025, and Q4 2025 are not provided in the filings (only six-month and full-year periods).
  • Full-year 2026 results are not available.
  • Net leverage ratio and interest coverage ratio as of June 30, 2026 are not disclosed.
  • Detailed debt maturity schedule beyond the Term Loan A Facility and Senior Notes described in the 10-K.
  • Impact of the Walking Dead Universe licensing agreement with Netflix (announced July 30, 2026) on future revenue and cash flow.
  • Outcome and potential liability of the MFN Litigation referenced in SG&A increases.
  • Breakdown of content licensing revenue by title/timing to assess sustainability.
Long US-equity 13F disclosures only · up to 45-day reporting lag · sells = reduce/avoid, not short. JSON: /api/signals · /api/funds · /api/status